ストックスクリーナーアプリを入手
310.22
3.85%
-13.86
前日終値:
$324.08
開ける：
$322.82
24時間の取引高:
163.43K
Relative Volume:
0.16
時価総額：
$8.64B
収益：
$1.77M
当期純損益:
$-123.74M
株価収益率:
-33.83
EPS:
-9.17
ネットキャッシュフロー:
$-95.21M
1週間 パフォーマンス:
+4.40%
1か月 パフォーマンス:
+14.17%
6か月 パフォーマンス:
+464.90%
1年 パフォーマンス:
+298.16%
1日の値動き範囲:
$310.00
$326.83
1週間の範囲:
$294.29
$326.91
52週間の値動き範囲:
$26.70
$326.91
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
名前
Praxis Precision Medicines Inc
セクター
電話
617-300-8460
住所
99 HIGH STREET, 30TH FLOOR, BOSTON
PRAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
311.51 | 8.99B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.89 | 112.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
740.47 | 77.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.23 | 50.10B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
355.48 | 46.97B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
342.22 | 36.99B | 4.98B | 69.59M | 525.67M | 0.5197 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-15 | 繰り返されました | Oppenheimer | Outperform |
| 2025-11-19 | 開始されました | BTIG Research | Buy |
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-07 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-03 | 繰り返されました | H.C. Wainwright | Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Buy |
| 2024-08-05 | 開始されました | Oppenheimer | Outperform |
| 2024-06-24 | 開始されました | Needham | Buy |
| 2024-06-18 | 開始されました | Guggenheim | Buy |
| 2024-05-01 | 開始されました | Robert W. Baird | Outperform |
| 2023-09-19 | 開始されました | Truist | Buy |
| 2022-06-06 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-26 | 開始されました | BofA Securities | Buy |
| 2021-04-26 | 開始されました | William Blair | Outperform |
| 2020-11-11 | 開始されました | Wedbush | Outperform |
| 2020-11-10 | 開始されました | Cowen | Outperform |
| 2020-11-10 | 開始されました | Evercore ISI | Outperform |
| 2020-11-10 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Praxis Precision Medicines Inc (PRAX) 最新ニュース
Praxis speeds up R&D plans for seizure therapy after FDA feedback - MSN
Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines stock hits 52-week high at $318.24 By Investing.com - Investing.com Nigeria
Praxis Precision Medicines (PRAX) Valuation As NDA Plans And New Clinical Leadership Point To Commercial Transition - Sahm
Praxis Precision Medicines stock hits 52-week high at $318.24 - Investing.com
PRAX Stock Price, Forecast & Analysis | PRAXIS PRECISION MEDICINES I (NASDAQ:PRAX) - Chartmill
Behavioral Patterns of PRAX and Institutional Flows - Stock Traders Daily
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Praxis Precision Medicines, Inc. (PRAX) a Strong Buy, Per Wall Street Consensus - Insider Monkey
Praxis Precision Medicines plans two NDA submissions by mid-February - Investing.com Nigeria
Aug PreEarnings: Can Praxis Precision Medicines Inc outperform in the next rallyPortfolio Value Summary & Free Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Is Praxis Precision Medicines (PRAX) Price Missing The Story After A 326% One-Year Surge? - Sahm
Praxis Precision Medicines (PRAX) stock jumps after Devinsky hire as FDA filings loom - TechStock²
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Up 7%Here's Why - MarketBeat
Praxis Precision Medicines (PRAX) Price Target Increased by 14.92% to 471.78 - Nasdaq
Praxis Precision Medicines Appoints Global Epilepsy Leader Dr. Orrin Devinsky as Head of Clinical Strategy - PharmiWeb.com
Is It Too Late To Reassess Praxis Precision Medicines (PRAX) After Its 1-Year Surge? - Yahoo Finance
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering - Investing News Network
Buyout Rumor: Can Praxis Precision Medicines Inc deliver consistent dividendsJuly 2025 Trends & Smart Money Movement Alerts - baoquankhu1.vn
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy - Quiver Quantitative
Praxis Precision Medicines Appoints Orrin Devinsky as Head of Clinical Strategy - marketscreener.com
US Biotech Share Sales Deliver Biggest First Week Since 2021 - Bloomberg.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 6.1%Here's Why - MarketBeat
Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress - Investing News Network
Praxis Precision Medicines (PRAX) Sets Ambitious Targets for 202 - GuruFocus
PRAX: Wedbush Raises Price Target Despite "Underperform" Rating - GuruFocus
Wedbush Forecasts Strong Price Appreciation for Praxis Precision Medicines (NASDAQ:PRAX) Stock - MarketBeat
Needham analyst keeps a buy rating on Praxis Precision Medicines, Inc. (PRAX) - MSN
Needham Analyst Keeps a Buy Rating on Praxis Precision Medicines, Inc. (PRAX) - Yahoo Finance
20 Best Performing Stocks in 2025 - Insider Monkey
Will Praxis Precision Medicines Inc. stock see PE expansionPerformance Line Overview & quick comparison of popular models - ulpravda.ru
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biopharmaceutical company uses stock grants to attract three new employees - Stock Titan
How Praxis’s Big Equity Raise, Ulixacaltamide Breakthrough Status And Board Shake-Up At Praxis Precision Medicines (PRAX) Has Changed Its Investment Story - Sahm
Praxis Precision (PRAX) Announces Key Leadership Changes - GuruFocus
Praxis Precision Medicines appoints new board members, promotes executives By Investing.com - Investing.com India
Praxis Precision Medicines appoints new board members, promotes executives - Investing.com
Praxis Precision Medicines Announces Key Management Appointments - TradingView — Track All Markets
Praxis Precision Medicines Announces New Board Appointments and Executive Promotions to Drive Growth and Commercial Readiness - Quiver Quantitative
Praxis Precision Medicines, Inc. Announces Management Changes - marketscreener.com
Will Praxis Precision Medicines Inc. stock reach all time highs in 2025 - ulpravda.ru
How strong is Praxis Precision Medicines Inc. stock balance sheet2025 Trading Volume Trends & AI Powered Buy and Sell Recommendations - ulpravda.ru
Will Praxis Precision Medicines Inc. stock benefit from commodity pricesJuly 2025 Volume & Real-Time Market Sentiment Alerts - ulpravda.ru
S P Trends: Is Praxis Precision Medicines Inc. stock a smart buy before Fed meeting2025 Technical Patterns & Expert Approved Trade Ideas - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a smart buy before Fed meetingJuly 2025 Selloffs & Real-Time Stock Movement Alerts - ulpravda.ru
Is Praxis Precision Medicines Inc. stock a buy in volatile marketsJuly 2025 EndofMonth & Capital Efficient Trade Techniques - ulpravda.ru
Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments - FinancialContent
Praxis rises on ulixacaltamide gaining Breakthrough Therapy status - MSN
Praxis Precision Medicines Inc (PRAX) 財務データ
収益
当期純利益
現金流量
EPS
Praxis Precision Medicines Inc (PRAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 20 '25 |
Sale |
193.09 |
25,130 |
4,852,256 |
20,832 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Option Exercise |
61.12 |
13,600 |
831,257 |
24,042 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 20 '25 |
Sale |
192.08 |
13,600 |
2,612,244 |
10,442 |
0.52%
4.28%
大文字化:
|
ボリューム (24 時間):